Back to search results
NCT06066580

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Enrolling by Invitation
PHASE2All AgesInterventionalTreatment
Edgewise Therapeutics, Inc.
~260 participants
Updated 2026-09-17 on ClinicalTrials.gov
What's tested:Sevasemten

At a glance

Recruiting sites
0 of 48 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of adverse events in those treated with sevasemten
Measured over 55 Months
+1 more outcome measured

Conditions

Becker Muscular Dystrophy

Explore related trials

Becker's Muscular Dystrophy

NCT06066580

Where you'd take part

This study runs at 48 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AP-HP Hopital Pitie-Salpetriere

    Paris, France, Franceno site contact published

  • Arkansas Children's Hospital

    Little Rock, Arkansasno site contact published

  • Azienda Ospedale - Università Padova

    Padova, Italy, Italyno site contact published

  • Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone

    Marseille, France, Franceno site contact published

  • Centre Hospitalier Régional de la Citadelle

    Liége, Belgium, Belgiumno site contact published

  • CHU de Nantes

    Nantes, France, Franceno site contact published

  • CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires

    Nice, France, Franceno site contact published

  • Fondazione IRCCS Ca'Granda Ospedale Maggiore

    Milan, Italy, Italyno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joanne M. Donovan, MD, PhD · STUDY_CHAIR · Edgewise Therapeutics, Inc.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

EDG-5506-002 ARCH: Complete the final study Visit 27 \[Month 24\]; or, completion of the ET visit prior to Visit 27 \[Month 24\]
EDG-5506-201 CANYON and GRAND CANYON: Complete the final study visit (Cohorts 1, 2, 4, and 5: Visit 12 \[Month 12\]; Cohort 6: Visit 11 \[Month 18\])
EDG-5506-202 DUNE: Complete at least 36 weeks of open-label treatment (Visit 14 \[Week 52\])

What this trial measures

  • Number of adverse events in those treated with sevasemten55 Months
  • Severity of adverse events in those treated with sevasemten55 Months